Product Center
Recombinant Herpes Zoster Vaccine (CHO Cells) IND Application Approved
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-13
- Views:
(Summary description)On August 12, 2024, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly applied for an IND application for a Class I new drug, "Recombinant Herpes Zoster Vaccine (CHO Cells)", which was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
Recombinant Herpes Zoster Vaccine (CHO Cells) IND Application Approved
(Summary description)On August 12, 2024, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly applied for an IND application for a Class I new drug, "Recombinant Herpes Zoster Vaccine (CHO Cells)", which was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-13 16:38
- Views:
On August 12, 2024, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly applied for an IND application for a Class I new drug, "Recombinant Herpes Zoster Vaccine (CHO Cells)", which was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
Herpes zoster (HZ) is a kind of infectious disease that mainly affects nerves and skin caused by reactivation of Varicella zoster virus (VZV). The main characteristic is clustered blisters distributed in a band shape, accompanied by obvious neuropathic pain, which becomes more severe with age. This disease is common in elderly, immunocompromised, and immunosuppressed patients, and has a certain recurrence rate. At present, there is no effective treatment for shingles, and vaccination is the preferred and effective means of preventing shingles.
Source: Government Service Website of the Center for Drug Evaluation of the National Medical Products Administration
The recombinant herpes zoster vaccine (CHO cells) approved this time utilizes the company's multiple independent intellectual property innovative technologies and officially authorized high-expression cell matrix, especially the independently developed and screened innovative adjuvant system, which has obvious advantages and eliminates dependence on foreign adjuvant technology. Preclinical studies have shown that this product can induce the production of high levels of specific antibodies and CD4+ T cell responses simultaneously, with high immunogenicity and safety. At the same time, the R&D team has optimized the production process to make it easier to scale up and achieve higher protein production, making subsequent commercial production more convenient and efficient.
Recently, the company's drug production license change has been approved by the Jiangsu Provincial Drug Administration, adding the production scope of "influenza virus subunit vaccine", marking the company's successful acquisition of the production license for trivalent influenza virus subunit vaccine. This is an unremitting effort made by the company in response to the WHO's recommendation this year that influenza vaccines should no longer include B/Yamagata lineage components. The company acted quickly to meet market demand and achieve the early launch of trivalent influenza virus subunit vaccines, scientifically respond to influenza prevention and control, and provide multiple influenza vaccine options for society!
Relevant information
-
The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. - Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
